Tarsus Pharmaceuticals Inc (TARS)
46.65
+0.15
(+0.32%)
USD |
NASDAQ |
Nov 14, 16:00
46.49
-0.16
(-0.34%)
After-Hours: 16:36
Tarsus Pharmaceuticals Total Liabilities (Quarterly): 124.60M for June 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 124.60M |
| March 31, 2024 | 74.07M |
| December 31, 2023 | 68.50M |
| September 30, 2023 | 54.67M |
| June 30, 2023 | 41.20M |
| March 31, 2023 | 37.81M |
| December 31, 2022 | 34.96M |
| September 30, 2022 | 33.84M |
| June 30, 2022 | 31.32M |
| Date | Value |
|---|---|
| March 31, 2022 | 32.29M |
| December 31, 2021 | 12.18M |
| September 30, 2021 | 11.27M |
| June 30, 2021 | 10.98M |
| March 31, 2021 | 10.72M |
| December 31, 2020 | 5.992M |
| September 30, 2020 | 110.01M |
| June 30, 2020 | 3.872M |
| December 31, 2019 | 64.32M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
3.872M
Minimum
Jun 2020
124.60M
Maximum
Jun 2024
42.37M
Average
34.40M
Median
Total Liabilities (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 607.73M |
| CEL-SCI Corp | 15.60M |
| AIM ImmunoTech Inc | 9.613M |
| IGC Pharma Inc | 2.714M |
| NovaBay Pharmaceuticals Inc | 4.542M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 376.84M |
| Shareholders Equity (Quarterly) | 252.25M |
| Debt to Equity Ratio | 0.2838 |
| Current Ratio | 7.031 |
| Net Debt Paydown Yield | -0.91% |